Bausch HealthMEX:BHCN 48 PEG Ratio is 0.32 as of Jun. 26, 2026, which is 14% below its 10-year median of 0.37. GuruFocus rates MEX:BHCN with a GF Score™ of 48/100 and a GF Value™ of MXN188.23 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 348 Drug Manufacturers companies, Bausch Health ranks better than 93.68% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Bausch Health's PEG Ratio or its related term are showing as below:
MEX:BHCN'
s PEG Ratio Range Over the Past 10 Years
Min: 0.06 Med: 0.37 Max: 43.41
Current: 0.35
During the past 13 years, Bausch Health's highest PEG Ratio was 43.41. The lowest was 0.06. And the median was 0.37.
MEX:BHCN's PEG Ratio is ranked better than 93.68% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.725
vs MEX:BHCN: 0.35
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Bausch Health (MEX:BHCN) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Bausch Health PEG Ratio Related Terms
Bausch Health PEG Ratio Historical Data
* Premium members only.
The historical data trend for Bausch Health's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Bausch Health's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Bausch Health (MEX:BHCN) has a PEG Ratio of 0.32 as of Jun. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Bausch Health and its competitors. This is 14% below median its historical median of 0.37. Over the past decade, Bausch Health's PEG Ratio has ranged from 0.06 to 43.41. According to the industry distribution chart, Bausch Health ranks #22 out of 348 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Bausch Health's PEG Ratio too high?
Bausch Health's current PEG Ratio of 0.32 is 14% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 43.41. The Drug Manufacturers industry median PEG Ratio is 1.73. Bausch Health's value of 0.32 is 81.4% below this industry median. Based on the distribution chart, Bausch Health ranks #22 out of 348 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bausch Health has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #22 out of 348 companies for PEG Ratio. This places Bausch Health in the top 6% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.73. Bausch Health's value of 0.32 is 81.4% below this benchmark. Historically, Bausch Health's own PEG Ratio has ranged from 0.06 to 43.41 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 1.73, Bausch Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.73, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current PEG Ratio of 0.32 is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current PEG Ratio is 0.32, which is 14% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (MEX:BHCN) is currently considered Possible Value Trap. The stock's GF Value™ is MXN188.23, compared to a current price of MXN85.44 — trading 54.6% below its estimated fair value. The current PEG Ratio is 0.32, which is 14% below median its 10-year median of 0.37 and 81.4% below the Drug Manufacturers industry median of 1.73. Bausch Health's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Bausch Health (MEX:BHCN), the current PEG Ratio is 0.32 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (MEX:BHCN) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of MXN85.44 is trading 54.6% below its estimated GF Value™ of MXN188.23.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for MEX:BHCN:
PEG Ratio: 0.32 (14% below median its 10-year median of 0.37)
GF Value™: MXN188.23 vs. price of MXN85.44 (54.6% below fair value)
Industry Position: 81.4% below the Drug Manufacturers median (#22 of 348)
No single metric tells the full story. See the MEX:BHCN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
48GF Score
Get the complete analysis for MEX:BHCN
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BHCN has been successfully added to your 
